229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0229
Abstract: Background Immune checkpoint inhibitors (ICI) have greatly improved the treatment options for patients with metastatic melanoma. Yet, a large percentage of melanoma patients do not respond to ICIs, there is a need for biomarkers that… read more here.
Keywords: melanoma; clinical benefit; response; first line ... See more keywords
Two patients from Turkey with a novel variant in the GM2A gene and review of the literature
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Pediatric Endocrinology and Metabolism"
DOI: 10.1515/jpem-2020-0655
Abstract: Abstract Objectives GM2 gangliosidosis is a rare form of inborn errors of metabolism including Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency. GM2 activator protein deficiency is an ultra-rare form of GM2 gangliosidosis. To date,… read more here.
Keywords: protein deficiency; gm2 activator; activator; activator protein ... See more keywords